American Society of Hematology

Fig. 2.

$Fig. 2. EBV DNA load dynamics in unfractionated whole blood of PTLD patient nos. 1 and 2. / (A) Patient no. 1 developed 3 episodes of PTLD after primary EBV infection, all preceded by increased EBV DNA loads. (B) Patient no. 2 was converted from cyclosporine A to FK506 as therapy for chronic rejection, which was followed by dramatically increasing EBV DNA loads that fluctuated strongly. EBV+ plasmacytoma in the mouth was diagnosed approximately 300 days later. Black boxes indicate acyclovir treatment and white boxes indicate gancyclovir treatment.$

EBV DNA load dynamics in unfractionated whole blood of PTLD patient nos. 1 and 2.

(A) Patient no. 1 developed 3 episodes of PTLD after primary EBV infection, all preceded by increased EBV DNA loads. (B) Patient no. 2 was converted from cyclosporine A to FK506 as therapy for chronic rejection, which was followed by dramatically increasing EBV DNA loads that fluctuated strongly. EBV⁺ plasmacytoma in the mouth was diagnosed approximately 300 days later. Black boxes indicate acyclovir treatment and white boxes indicate gancyclovir treatment.

This Feature Is Available To Subscribers Only